Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

40 mcg/day

60 mcg/day

80 mcg/dayMean baseline HbA1c (%)

7.96

7.79

8.05

8.03Mean week 24 HbA1c (%)

7.07

6.93

6.67

6.67Mean HbA1c change at week 24

-0.89

-0.86

-1.38

-1.36HbA1c  < 7% at week 24

60%

71%

73%

79%Mean weight change at week 24 (lbs)

-1.8

-7.9

-6.8

-7.7"The reductions in HbA1c and weight are substantial, especially for a group of patients on metformin-only background therapy with baseline HbA1c levels at 8.0 percent.  We look forward to evaluating optimized dose regimens of ITCA 650 in broader patient populations in the phase 3 program," Graves said.

ITCA 650 therapy in the phase 2 trial was administered for the 90-day treatment period with a single insertion of ITCA 650 on day 1 and removal on or around day 90. The extension phase of the 2 trial evaluated higher doses of ITCA 650 using a single device to deliver 3 months of treatment. The phase 3 study planned for early 2011 will evaluate treatment regimens involving initial 12-week ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day thereafter using even longer duration ITCA 650 devices.

A downloadable version of the ITCA 650 phase 2 presentation from EASD is available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2 diabetes consists of DUROS continuous subcutaneous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy. Intarcia's proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

The DUROS technology can
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)...  Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... the prior year. Reported sales increased 5% which included ... per diluted share as reported (EPS) were $2.49, compared ... EPS was $2.57, an increase of 9% over the ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has accepted  Damian Finio,s ... has accepted a senior level finance position at a ... of his new position, Mr. Finio will be unable ... Laboratories, Inc.  The effective date of his resignation will ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... 2012   OncoSec Medical Incorporated (OTCBB:ONCS), which ... ElectroOncology therapies to treat solid tumor cancers, today ... biomarker strategy with the goal of identifying and ... the selection of patients potentially responsive to the ...
... 8, 2012  S1 Pharmaceuticals, Inc., a developer of therapeutics for ... addition and Scientific Advisory Board appointment to strengthen and expand ... Pyke, MD, PhD, a member of the S1 Advisory Board ... Chief Medical Officer. , Molly A. Katz, MD was ...
Cached Medicine Technology:OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy 2OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy 3S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments 2S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments 3
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key market ... value, in millions of US dollars, volume (in units) ... – Rigid Non-Video Sinuscopes. , The report also provides ... these market categories, and global corporate-level profiles of the ... related to the Sinuscopes market wherever available. , Overview ...
(Date:7/26/2014)... 26, 2014 Multiple sclerosis (MS), ... is an inflammatory disease in which the insulating ... spinal cord are damaged. This damage disrupts the ... communicate, resulting in a wide range of signs ... problems. Multiple sclerosis takes several forms, with new ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... by Vkool.com, this is a comprehensive bodybuilding program that ... without using anabolic steroids . The program also ... muscle without cardio. , Vkool reveals in its ... and workouts that can help men get ripped and ...
(Date:7/25/2014)... 26, 2014 Dental Perfection, a Derby ... services including general dentistry, clear braces and much more, ... this year in Derby. The new practice, which is ... Medical Centre in Littleover, Derby. Patients may already pre-register ... The new dental practice, which is headed by Invisalign ...
(Date:7/25/2014)... 26, 2014 According to a ... by Product (vibration monitoring, thermography, ultrasound emission, lubricating ... Component, Application and Geography - Global Forecast to ... health monitoring market is expected to reach $2.50 ... 2020. , Browse 117 market data Tables and ...
Breaking Medicine News(10 mins):Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
... ... of its new website, Herbal Fen Phen Lawyers ( http://www.herbalfenphenlawyers.com/ ). Herbal Fen Phen ... despite warnings from the FDA that herbal Fen Phen may be linked to serious ... death. , ...
... , OAKLAND, Calif., Aug. 7 Kaiser ... reported today a combined total operating revenue of $10.5 billion for ... the second quarter of last year. Operating income in the ... quarter of last year. Net non-operating income was $209 million ...
... , Senate Finance Committee Urged Not to ... , WASHINGTON, Aug. 7 America,s local and regional ... a provision imposing a 20% co-pay on laboratory services under Medicare. ... system, this provision would shift billions of dollars in costs to ...
... , PROVO, Utah, Aug. 7 Nu ... board of directors has declared a quarterly dividend of $0.115 per ... of record on Aug. 28, 2009. , , ... Inc. has been demonstrating its tradition of innovation through its comprehensive ...
... risk factors and patterns of development , FRIDAY, Aug. ... second grade for symptoms of depression may help better ... of Washington study shows. , Even though about ... developed more than a few symptoms of depression, the ...
... , , , , ... WBMD ) and HLTH Corporation (Nasdaq: HLTH ) today announced ... 29th Annual Global Growth Conference on Wednesday, August 12, 2009 at 1:00 ... the general public are invited to listen to a live audio broadcast ...
Cached Medicine News:Health News:Hissey Kientz Announces the Launch of Herbal Fen Phen Lawyers Website 2Health News:Hissey Kientz Announces the Launch of Herbal Fen Phen Lawyers Website 3Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 4Health News:Seniors: Get Your Checkbooks Ready 2Health News:Signs of Depression Noted in Second Graders 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: